reports
Regeneron Reports First Quarter 2024 Financial and Operating Results
Regeneron Reports First Quarter 2024 Financial and Operating Results First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP diluted EPS of $6.27 and non-GA...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of E...
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generatio...
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and...
- Charlotte Vaisse
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Konrad Zomer
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/25/2024
Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...
LHN LAFARGEHOLCIM LTD.
REL RELX PLC
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
WCH WACKER CHEMIE AG
CA CARREFOUR SA
BVI BUREAU VERITAS SA
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
ORA ORANGE SA
RI PERNOD RICARD SA
ULVR UNILEVER PLC
GLE SOCIETE GENERALE S.A. CLASS A
NESN NESTLE S.A.
ENI ENI S.P.A.
BAS BASF SE
SAN SANOFI
VOW3 VOLKSWAGEN AG PREF
SY1 SYMRISE AG
01913 PRADA S.P.A.
REP REPSOL SA
MOCORP METSO OUTOTEC OYJ
KGX KION GROUP AG
MONC MONCLER SPA
ASSA B ASSA ABLOY AB CLASS B
IBE IBERDROLA SA
AZN ASTRAZENECA PLC
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
HFG HELLOFRESH SE
ADYEN ADYEN NV
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
DSY DASSAULT SYSTEMES SA
AZE AZELIS GROUP NV
ATCO A ATLAS COPCO AB
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
DSFIR KONINKLIJKE DSM N.V.
- Charlotte Vaisse
- Emmanuel Matot
- Jean-Baptiste Rouphael
- Konrad Zomer
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/04/2024
Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...
LHN LAFARGEHOLCIM LTD.
REL RELX PLC
GET GETLINK SE
IPN IPSEN SA
EQNR EQUINOR ASA
WCH WACKER CHEMIE AG
CA CARREFOUR SA
BVI BUREAU VERITAS SA
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
ORA ORANGE SA
RI PERNOD RICARD SA
ULVR UNILEVER PLC
GLE SOCIETE GENERALE S.A. CLASS A
NESN NESTLE S.A.
ENI ENI S.P.A.
BAS BASF SE
SAN SANOFI
VOW3 VOLKSWAGEN AG PREF
SY1 SYMRISE AG
01913 PRADA S.P.A.
REP REPSOL SA
MOCORP METSO OUTOTEC OYJ
KGX KION GROUP AG
MONC MONCLER SPA
ASSA B ASSA ABLOY AB CLASS B
IBE IBERDROLA SA
AZN ASTRAZENECA PLC
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
HFG HELLOFRESH SE
ADYEN ADYEN NV
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
DSY DASSAULT SYSTEMES SA
AZE AZELIS GROUP NV
ATCO A ATLAS COPCO AB
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
DSFIR KONINKLIJKE DSM N.V.
- Damien Choplain
- Martial Descoutures
AstraZeneca : Very reassuring Q1 supports 2024 targets
>Symbicort and Farxiga lead the way - AZN has reported much stronger than expected Q1 2024 results, mainly thanks to Farxiga and Symbicort. Revenue increased by 19% at constant exchange rates, boosted by CVRM (cardio and metabolism) and Oncology. Sales came out 7% higher than expected. Although penalised by a recent reduction in prices for Tagrisso (June 23), Imfinzi (February 24) and Faslodex in China (November 23), revenue in China increased by 13%. However, th...
- Damien Choplain
- Martial Descoutures
AstraZeneca : Un T1 extrêmement rassurant confirmant les ambitions 202...
>Symbicort et Farxiga mènent la danse - AZN vient de publier ses résultats du T1 24 qui se révèlent nettement supérieurs aux attentes du fait notamment de Farxiga et Symbicort. Les revenus sont en hausse de 19% à tcc tirés par sa franchise CVRM (cardio metabolique) et Oncologie. Les ventes ressortent ainsi 7% au-dessus des attentes. Bien que pénalisée par une baisse de prix récentes de Tagrisso (Juin 23), Imfinzi (Fevr 24) et Faslodex en Chine (Nov 23), la Chine est e...
- ABGSC Healthcare Research
- Alexander Krämer
- Morten Larsen
Regeneron to Showcase Progress in Advancing Novel Investigational Trea...
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo® (cemiplimab-rwlc) 17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Reg...
Regeneron to Highlight Advances in Genetic Medicine Research at Americ...
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be pres...
- Dominic Rose
- Naresh Chouhan
AZN - Upgrade to BUY (TP £125 [£115], 16 pgs)
Having been neutral on AZN since Feb ‘23 based on what we believed to be a lack of catalysts & over optimistic consensus forecasts, we show that most of the EPS downgrades are in no’s & the catalyst outlook is transformed. Our deep dive on the pipeline leads us to upgrade our 2029 sales by $8bn, giving us 5% CAGR sales growth 2024-29 and 9% EPS CAGR. We conducted deep research into 6 key drugs which drive the bulk of our 7% above consensus 2029 sales forecasts. The biggest impediments to AZN sha...
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 04/11/2024
Waga Energy offers an innovative start-up profile in the utilities sector: i/ disruptive technology in biogas treatment, ii/ established competitive advantages, iii/ positioning on a market with strong potential (>20,000 landfills) and iv/ a robust business model based on recurring revenues. At its CMD in February 2024, the company reconfirmed its ambitions for 2026 set out at the IPO (contracts for 4 TWh and recurring revenues of € 200m). The financing secured in Q1 2024 (€ 112m base...
- Martin Marandon-Carlhian
- Stephane Houri
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 11/04/2024
Waga Energy propose un profil de start-up innovante dans le secteur des utilities : i/ une technologie disruptive pour le traitement du biogaz, ii/ des avantages compétitifs établis, iii/ un positionnement sur un marché à fort potentiel (>20 000 décharges) et iv/ un modèle robuste de revenus récurrents. La société a reconfirmé lors du CMD en février 2024 ses ambitions à horizon 2026 annoncées au moment de son IPO (signature de 4 TWh et CA récurrent de 200 M€). Fort des financements ob...
- Martin Marandon-Carlhian
- Stephane Houri
- Team Pharma
ODDO : Q1 2024 will not set the tone for the year
>Renewed interest in the sector on the stock market since the start of the year - After a challenging end to the year for the pharma sector in 2023, it has picked up since the start of the year (our coverage +15% vs Stoxx 600 +7%). Novo Nordisk continues to be the driver (+26% in Q1) aided by the re-rating of GSK (+18%). Novartis has also contributed, albeit to a lesser extent, with a gain of 3% in Q1. Sanofi, AstraZeneca and Roche bring up the rear, with gains of 1% ...
- Team Pharma
ODDO : Le T1 2024 ne donnera pas le ton de l’année
>Un regain d’intérêt pour le secteur en Bourse depuis le début de l’année - Après une fin d’année difficile pour le secteur, la pharma a repris des couleurs depuis le début d’année (coverage +15% vs Stoxx 600 +7%). Novo Nordisk continue de jouer son rôle de locomotive (+26% lors du T1) aidé par le rerating de GSK (+18%). Dans une moindre mesure, Novartis affiche une performance de 3% lors de ce T1. Sanofi, AstraZeneca et Roche ressortent en queue de peloton à 1%, +0.7...
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response R...
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM...
Regeneron to Report First Quarter 2024 Financial and Operating Results...
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 2, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.